Chea Neitzel

Senior Territory Manager at BDPI

Role: Territory Manager at Intrinsic Therapeutics, Inc
Location: Columbus, OH, US
LinkedIn followers: 500 followers

Sales & Business DevelopmentView LinkedIn profile

Experience

Territory Manager
Intrinsic Therapeutics, Inc
Mar 2024 — Present · Columbus, OH, US

Education

University of Notre Dame
B.S., Biology, 2nd Major French Literature
1992 — 1996
Missouri University of Science and Technology
M.S., Engineering Management
2000 — 2001

Skills

Process Improvement
Competitive Analysis
Medical Devices
Contract Negotiation
Strategic Planning
Sales Management
Strategy
Sales
Cross-Functional Team Leadership
Sales Operations
Aviation
Product Launch
Team Leadership
New Business Development
Business Development
Leadership
Program Management
Management
Team Building
Operations Management

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@barricaid.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Intrinsic Therapeutics, Inc

Medical Equipment Manufacturing · 91 employees · Founded 2000 · Woburn, Massachusetts, United States

Adjacent to a lumbar discectomy, the Barricaid® device is designed to close large defects in the annulus, which often lead to disc reherniation and/or disc collapse. Barricaid is a permanent implant with two components - a titanium bone anchor and a flexible polymer barrier. The barrier is designed to prevent reherniation by physically blocking the annulus at the post-surgery defect. The anchor component is comprised of titanium alloy that is placed into either the caudal or cranial-adjacent vertebral body to secure the device in position. The Barricaid has been studied in a definitive – level 1B evidence - randomized superiority trial with over 550 patients enrolled (clinicaltrials.gov NCT01••••38). The study focuses on patient at highest risk of reherniation and reoperation, enrolling only those patients with large defects (width >5 mm). The co-primary endpoints of reherniation and an 8-point composite of safety and effectiveness are evaluated at 2 years, with a parallel cost effectiveness analysis. Treated patients were found superior on both endpoints, with significantly lower rates of symptomatic recurrences (12% vs. 25%, p<0.001), index-level reoperations (9% vs. 16%, p=0.01), and device or procedure related serious adverse events (SAEs)(7% vs. 17%, p=0.001). Through two years, a total of 29 reoperations were performed in Barricaid subjects in comparison to 61 procedures in Controls. Study results are published in The Spine Journal, May 2018. Barricaid is FDA-Approved For full risk/benefit, see:

barricaid.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Experience

Territory Manager

Education

University of Notre Dame

Missouri University of Science and Technology

Skills

Find verified contacts for anyone on LinkedIn